MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- AJANTA PHARMA - TEVA PHARMA (Israel)
AJANTA PHARMA vs TEVA PHARMA (Israel) - Comparison Results
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 AJANTA PHARMA  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AJANTA PHARMA Mar-19 |
TEVA PHARMA Dec-13 |
AJANTA PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,422 | 2,973 | - | |
| Low | Rs | 898 | 2,582 | - | |
| Sales per share (Unadj.) | Rs | 233.5 | 1,706.1 | - | |
| Earnings per share (Unadj.) | Rs | 44.0 | 106.6 | - | |
| Cash flow per share (Unadj.) | Rs | 52.2 | 244.5 | - | |
| Dividends per share (Unadj.) | Rs | 9.00 | 93.30 | - | |
| Dividend yield (eoy) | % | 0.8 | 3.4 | 23.1% | |
| Book value per share (Unadj.) | Rs | 255.1 | 1,895.1 | - | |
| Shares outstanding (eoy) | m | 88.02 | 848.00 | - | |
| Bonus/Rights/Conversions | BB | - | - | ||
| Price / Sales ratio | x | 5.0 | 1.6 | 305.1% | |
| Avg P/E ratio | x | 26.4 | 26.1 | 101.2% | |
| P/CF ratio (eoy) | x | 22.2 | 11.4 | 195.7% | |
| Price / Book Value ratio | x | 4.5 | 1.5 | 310.2% | |
| Dividend payout | % | 20.5 | 87.5 | 23.4% | |
| Avg Mkt Cap | Rs m | 102,081 | 2,355,388 | 4.3% | |
| No. of employees | `000 | 6.8 | 44.9 | 15.1% | |
| Total wages/salary | Rs m | 4,307 | 0 | - | |
| Avg. sales/employee | Rs Th | 3,022.6 | 32,189.6 | 9.4% | |
| Avg. wages/employee | Rs Th | 633.4 | 0 | - | |
| Avg. net profit/employee | Rs Th | 569.1 | 2,010.9 | 28.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 20,554 | 1,446,763 | 1.4% | |
| Other income | Rs m | 211 | 0 | - | |
| Total revenues | Rs m | 20,765 | 1,446,763 | 1.4% | |
| Gross profit | Rs m | 5,664 | 396,197 | 1.4% | |
| Depreciation | Rs m | 721 | 116,943 | 0.6% | |
| Interest | Rs m | 12 | 28,417 | 0.0% | |
| Profit before tax | Rs m | 5,143 | 250,837 | 2.1% | |
| Minority Interest | Rs m | 0 | 1,140 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -164,661 | 0.0% | |
| Tax | Rs m | 1,273 | -3,062 | -41.6% | |
| Profit after tax | Rs m | 3,870 | 90,378 | 4.3% | |
| Gross profit margin | % | 27.6 | 27.4 | 100.6% | |
| Effective tax rate | % | 24.8 | -1.2 | -2,027.5% | |
| Net profit margin | % | 18.8 | 6.2 | 301.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,812 | 977,138 | 1.2% | |
| Current liabilities | Rs m | 3,776 | 852,147 | 0.4% | |
| Net working cap to sales | % | 39.1 | 8.6 | 452.5% | |
| Current ratio | x | 3.1 | 1.1 | 272.8% | |
| Inventory Days | Days | 77 | 91 | 85.2% | |
| Debtors Days | Days | 82 | 96 | 85.1% | |
| Net fixed assets | Rs m | 14,398 | 472,545 | 3.0% | |
| Share capital | Rs m | 175 | 3,561 | 4.9% | |
| Net worth | Rs m | 22,452 | 1,607,079 | 1.4% | |
| Long term debt | Rs m | 7 | 739,762 | 0.0% | |
| Total assets | Rs m | 26,962 | 3,306,317 | 0.8% | |
| Interest coverage | x | 444.3 | 9.8 | 4,521.6% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.1% | |
| Sales to assets ratio | x | 0.8 | 0.4 | 174.2% | |
| Return on assets | % | 14.4 | 3.6 | 400.7% | |
| Return on equity | % | 17.2 | 5.6 | 306.5% | |
| Return on capital | % | 23.0 | 4.9 | 465.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,748 | 230,539 | 1.6% | |
| From Investments | Rs m | -2,228 | -81,689 | 2.7% | |
| From Financial Activity | Rs m | -1,475 | -276,547 | 0.5% | |
| Net Cashflow | Rs m | 45 | -127,697 | -0.0% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.22 Rs / USD
Compare AJANTA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare AJANTA PHARMA With: VENUS REMEDIES DR. REDDYS LAB PIRAMAL ENTERPRISES SUVEN LIFESCIENCES ALKEM LABORATORIES
|
| |
Today's Market
Sensex Ends 246 Points Higher; Capital Goods and Power Stocks Witness Buying(Closing)
Extending gains to the sixth day, Indian share markets traded on a positive note most of the day and ended higher.
Related Views On News
AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)
Aug 2, 2019 | Updated on Aug 2, 2019For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)
May 3, 2019 | Updated on May 3, 2019For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)
Oct 14, 2019This is once in a decade opportunity to make a killing from smallcap rebound.
Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)
Oct 7, 2019Here's what every individual investor must know about Yes Bank...
Two Stocks to Buy in the Great Indian Festival (Profit Hunter)
Oct 11, 2019Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.
The One Stock I Like in this Market (The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)
Oct 11, 2019Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.
More|
| |
AJANTA PHARMA SHARE PRICE
Oct 18, 2019 03:37 PM
TRACK AJANTA PHARMA
- Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AJANTA PHARMA
AJANTA PHARMA 8-QTR ANALYSIS
COMPARE AJANTA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.